The estimated Net Worth of Jeffrey S Mathiesen is at least 8.15 千$ dollars as of 17 December 2021. Mr Mathiesen owns over 3,000 units of Helius Medical Technologies Inc stock worth over 3,150$ and over the last 4 years he sold HSDT stock worth over 0$. In addition, he makes 5,000$ as CFO & Treasurer at Helius Medical Technologies Inc.
Mr has made over 1 trades of the Helius Medical Technologies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of HSDT stock worth 15,930$ on 17 December 2021.
The largest trade he's ever made was buying 3,000 units of Helius Medical Technologies Inc stock on 17 December 2021 worth over 15,930$. On average, Mr trades about 273 units every 0 days since 2020. As of 17 December 2021 he still owns at least 3,937 units of Helius Medical Technologies Inc stock.
You can see the complete history of Mr Mathiesen stock trades at the bottom of the page.
Jeffrey S. Mathiesen CPA, CPA is the CFO & Treasurer at Helius Medical Technologies Inc.
As the CFO & Treasurer of Helius Medical Technologies Inc, the total compensation of Mr CPA at Helius Medical Technologies Inc is 5,000$. There are no executives at Helius Medical Technologies Inc getting paid more.
Mr CPA is 60, he's been the CFO & Treasurer of Helius Medical Technologies Inc since . There are no older and 2 younger executives at Helius Medical Technologies Inc.
Jeffrey's mailing address filed with the SEC is C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN, PA, 18940.
Over the last 9 years, insiders at Helius Medical Technologies Inc have traded over 0$ worth of Helius Medical Technologies Inc stock and bought 1,827,117 units worth 3,547,767$ . The most active insiders traders include Dane Andreeff、Blane Walter、Philippe Deschamps. On average, Helius Medical Technologies Inc executives and independent directors trade stock every 121 days with the average trade being worth of 58,628$. The most recent stock trade was executed by Dane Andreeff on 14 December 2023, trading 5,000 units of HSDT stock currently worth 40,500$.
helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.
Helius Medical Technologies Inc executives and other stock owners filed with the SEC include: